Cartesian Therapeutics Inc (NAS:RNAC)
$ 18.83 0.92 (5.14%) Market Cap: 478.56 Mil Enterprise Value: 274.02 Mil PE Ratio: 0 PB Ratio: 607.42 GF Score: 52/100

Q4 2022 Selecta Biosciences Inc Earnings Call Transcript

Mar 02, 2023 / 01:30PM GMT
Release Date Price: $47.4 (-1.25%)
Operator

Good morning, and welcome to the Selecta Bio Fourth Quarter 2022 Earnings Release Conference Call. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Blaine Davis, Chief Financial Officer. Please go ahead.

Blaine T. Davis
Selecta Biosciences, Inc. - CFO

Thank you, and good morning, everyone. Welcome to our fourth quarter and full year 2022 financial results and business update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website at www.selectabio.com in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed earlier this morning with the Securities and Exchange Commission or the SEC.

Joining me on today's call are Carsten Brunn, President and Chief Executive Officer; Kei Kishimoto, Chief Scientific Officer; and Peter Traber, our Chief Medical Officer. During today's call, we will be making certain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot